Skip to main content

Advertisement

SpringerLink
Log in

Adjunctive Therapy in Patients with Alzheimer’s Disease

A Practical Approach

  • Practical Therapeutics
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Alzheimer’s disease (AD) primarily results in memory impairment and cognitive deficits in areas such as language, visuospatial function, calculation, praxis and judgement. However, over 30% of patients with dementia develop a group of secondary behavioural disturbances, including depression, hallucinations and delusions, agitation, insomnia and wandering. Because these secondary symptoms impair patients’ function, increase their need for supervision, and often influence the decision to institutionalise them, the control of these symptoms is a priority in managing AD.

Psychotropic drugs, particularly antipsychotics (neuroleptics), have been a mainstay in treating many of these symptoms, but carry a high risk of adverse effects. Patients with AD may be particularly vulnerable to adverse effects of medications because of changes in pharmacokinetics and neurotransmitter systems, related to both AD and aging.

At present, treating secondary symptoms of AD is more of an art than a science. For virtually every group of symptoms, older and newer classes of medications are available, with proven efficacy in patients without dementia and less clear results in AD patients. We review current treatment options and suggest preferences for each symptom complex, based on a trade-off between efficacy and adverse effects.

New agents, such as selective serotonin reuptake inhibitors and atypical antipsychotics, may herald the arrival of symptom- (and receptor-) specific drugs with minimal adverse effects. Until the appropriate trials are conducted in patients with AD, including comparative studies of different agents, we recommend that clinicians select and use a few medications from the suggestions in this review, know their pharmacokinetic and half-life profiles in depth, and follow the general principles that apply to using any medication in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. United States Congress, Office of Technology Assessment. Losing a million minds: confronting the tragedy of Alzheimer’s disease and other dementias. Washington DC, 1987

    Google Scholar 

  2. Swearer J, Drachman D, O’Donnell B, et al. Troublesome and disruptive behaviors in dementia. J Am Geriatr Soc 1988; 36: 784–90

    PubMed  CAS  Google Scholar 

  3. Rubin E, Morris J, Berg L. The progression of personality change in senile dementia of the Alzheimer’s type. J Am Geriatr Soc 1987; 35: 721–5

    PubMed  CAS  Google Scholar 

  4. Chenoweth B, Spencer B. Dementia: the experience of family caregivers. Gerontologist 1986; 26: 267–71

    Article  PubMed  CAS  Google Scholar 

  5. Von Moite LJ, Greenblatt DJ, Harmatz JS, et al. Psychotropic drug metabolism in old age: principles and problems of assessment. In: Bloom FE, Kupier DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1461–9

    Google Scholar 

  6. Roth M. The natural history of mental disorder in old age. J Ment Sci 1955; 101: 201–301

    Google Scholar 

  7. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. Br J Psychiatry 1990; 157: 81–6

    Article  PubMed  CAS  Google Scholar 

  8. Rockwell E, Lam R, Zisook S. Antidepressant drug studies in the elderly. Psychiatr Clin North Am 1988; 11: 215–34

    PubMed  CAS  Google Scholar 

  9. Glassman A, Bigger JJ. Cardiovascular effects of therapeutic doses of the tricyclic antidepressants: a review. Arch Gen Psychiatry 1981; 38: 815–20

    Article  PubMed  CAS  Google Scholar 

  10. Feighner J, Boyer W, Meredith C, et al. An overview of fluoxetine in geriatric depression. Br J Psychiatry 1988; 153 Suppl. 3: 105–8

    Google Scholar 

  11. Schonewal M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 Suppl.: 34s–39s

    Google Scholar 

  12. Preskorn S. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 94(5A): 2S–12S

    PubMed  CAS  Google Scholar 

  13. Adolfsson R, Gottfries C, Oreland L, et al. Increased activity of brain and platelet monoamine oxidase in dementia of the Alzheimer type. Life Sci 1980; 27: 1029–34

    Article  PubMed  CAS  Google Scholar 

  14. Georgotas A, McCue R, Cooper T, et al. How effective and safe is continuation treatment in elderly depressed patients? Arch Gen Psychiatry 1988; 45: 929–32

    Article  PubMed  CAS  Google Scholar 

  15. Satel S, Nelson J. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989; 50: 241–9

    PubMed  CAS  Google Scholar 

  16. Feighner J, Herbstein J, Dambuji W. Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985; 46: 206–9

    PubMed  CAS  Google Scholar 

  17. Chiarello R, Cole J. The use of psychostimulants in general psychiatry: a reconsideration. Arch Gen Psychiatry 1987; 44: 286–95

    Article  PubMed  CAS  Google Scholar 

  18. Reifler B, Larson E, Teri L. Dementia of the Alzheimer’s type and depression. J Am Geriatr Soc 1986; 34: 855–9

    PubMed  CAS  Google Scholar 

  19. Gierz M, Zweifach M, Jeste D. The use of antidepressants in Alzheimer’s disease patients. In: Cummings J, Miller B, editors. Treatment of Alzheimer’s disease. New York: Marcell Dekker, 1989: 125–42

    Google Scholar 

  20. Reifler B, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer’s disease patients with and without depression. Am J Psychiatry 1989; 146: 45–9

    PubMed  CAS  Google Scholar 

  21. Tariot P, Cohen R, Sunderland T, et al. L-Deprenyl in Alzheimer’s disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987; 44: 427–33

    Article  PubMed  CAS  Google Scholar 

  22. Deutsch L, Bylsma F, Rovner B, et al. Psychosis and physical aggression in probable Alzheimer’s disease. Am J Psychiatry 1991; 148: 1151–63

    Google Scholar 

  23. Cohen-Mansfield J, Billing N. Agitated behavior in the elderly: a conceptual review. J Am Geriatr Soc 1986; 34: 711–21

    PubMed  CAS  Google Scholar 

  24. Wragg R, Jeste D. Overview of depression and psychosis in Alzheimer’s disease. Am J Psychiatry 1989; 146: 577–89

    PubMed  CAS  Google Scholar 

  25. Merriam M, Aronson M, Gaston P, et al. The psychiatric symptoms of Alzheimer’s disease. J Am Geriatr Soc 1988; 36: 7–12

    PubMed  CAS  Google Scholar 

  26. Teri L, Larson E, Reifler B. Behavioral disturbances in dementia of the Alzheimer’s type. J Am Geriatr Soc 1988; 36: 1–6

    PubMed  CAS  Google Scholar 

  27. Sunderland T, Silver M. Neuroleptics in the treatment of dementia. Int J Geriatr Psychiatry 1988; 3: 79–88

    Article  Google Scholar 

  28. Schneider L, Pollock V, Lyness S. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63

    PubMed  CAS  Google Scholar 

  29. Devanand D, Sackheim H, Brown R, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer’s disease. Neurology 1989; 46: 854–7

    CAS  Google Scholar 

  30. Gottlieb G, McAllister T, Gur R. Depot neuroleptics in the treatment of behavioral disorders in patients with Alzheimer’s disease. J Am Geriatr Soc 1988; 36: 642–4

    Google Scholar 

  31. Salzman C. Treatment of agitation in the elderly. In: Meitzer H, editor. Psychopharmacology: a generation of progress. New York: Raven Press, 1987: 1167–76

    Google Scholar 

  32. Sunderland T, Tariot P, Cohen R, et al. Anticholinergic sensitivity in patients with dementia of Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987; 44: 418–26

    Article  PubMed  CAS  Google Scholar 

  33. Barton R, Hurst L. Unnecessary use of tranquilizers in elderly patients. Br J Psychiatry 1966; 112: 989–90

    Article  PubMed  CAS  Google Scholar 

  34. Raskind M, Risse S, Lampe T. Dementia and antipsychotic drugs. J Clin Psychiatry 1987; 48 Suppl.: 16–8

    PubMed  Google Scholar 

  35. Peabody C, Warner D, Whiteford H, et al. Neuroleptics and the elderly. J Am Geriatr Soc 1987; 35: 233–8

    PubMed  CAS  Google Scholar 

  36. Jenike M. Tardive dyskinesia: special risk in the elderly. J Am Geriatr Soc 1983; 31: 71–3

    PubMed  CAS  Google Scholar 

  37. Baldessarini R, Frankenburg R. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746–54

    Article  PubMed  CAS  Google Scholar 

  38. Salzman C, Shader R, Greenblatt D, et al. Short half-life of benzodiazepines in the elderly. Arch Gen Psychiatry 1983; 40: 293–7

    Article  PubMed  CAS  Google Scholar 

  39. Pomara N, Stanley B, Block R, et al. Increased sensitivity of the elderly to the central depressant effects of diazepam. J Clin Psychiatry 1985; 46: 185–7

    PubMed  CAS  Google Scholar 

  40. Sunderland T, Weigartner T, Cohen R, et al. Low-dose oral lorazepam administration in Alzheimer’s subjects and age-matched controls. Arch Gen Psychiatry 1987; 44: 418–26

    Article  PubMed  CAS  Google Scholar 

  41. Prinz P, Vitiello M, Raskind M. Geriatrics: sleep disorders and aging. N Engl J Med 1991; 323: 520–6

    Google Scholar 

  42. Salzman C, Fisher J, Nobel K, et al. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 1992; 7: 89–93

    Article  Google Scholar 

  43. Weiler P, Mungas D, Bernick C. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1988; 1: 226–30

    Article  PubMed  CAS  Google Scholar 

  44. Kramer C. Methaqualone and chloral hydrate: preliminary comparison in geriatric patients. J Am Geriatr Soc 1967; 15: 455–61

    PubMed  CAS  Google Scholar 

  45. Goldstein S, Birnbom F, Lancee W, et al. Comparison of oxazepam, flurazepam and chloral hydrate as hypnotic sedatives in geriatric patients. J Am Geriatr Soc 1978; 26: 366–71

    PubMed  CAS  Google Scholar 

  46. Reynolds C, Hoch C, Monk T. Sleep and chronobiologic disturbances in late life. In: Busse E, Blazer D, editors. Geriatric psychiatry. Washington, DC: American Psychiatric Association, 1989: 475–88

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Service, Veterans Affairs Medical Center, and Department of Neurosciences, University of California, San Diego, California, USA

    Jody Corey-Bloom & Douglas Galasko

Authors
  1. Jody Corey-Bloom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas Galasko
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corey-Bloom, J., Galasko, D. Adjunctive Therapy in Patients with Alzheimer’s Disease. Drugs & Aging 7, 79–87 (1995). https://doi.org/10.2165/00002512-199507020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199507020-00002

Keywords

Search

Navigation